FindTrial
Sign In

Study on the efficacy, safety and population Pharmacokinetics (PPK) of high dose tigecycline in patients with hospital acquired pneumonia (HAP)

Study on the efficacy, safety and population Pharmacokinetics (PPK) of high dose tigecycline in patients with hospital acquired pneumonia (HAP)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16008883
Enrollment
Unknown
Registered
2016-07-22
Start date
2016-07-07
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hospital acquired pneumonia

Interventions

2:Non intervention

Sponsors

The second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged greater than 18 years, male and female; 2. Continuous use of the treatment for longer than 5 days.

Exclusion criteria

Exclusion criteria: 1. use tigecycline due to the infection of other parts (such as abdominal, skin and soft tissue) ; 2. May be allergic to, or other severe allergic history who have an effect on the study; 3. Due to other circumstances, the researchers think it is not appropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Clinical cure rate;—

Countries

China

Contacts

Public ContactHai Bin Dai

The second Affiliated Hospital, School of Medicine, Zhejiang University

haibindai@163.com+86 13600527604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026